In the latest period of Q4'25, Pfizer's (PFE) Gross Margin stands at 70%, reflecting a moderate decline from the prior quarter's 74.9%. Operating Margin has turned negative at -9.4%, indicating operational challenges, while Net Profit Margin is also negative at -9.4%, marking a sharp drop from Q3'25's positive 21.3% and highlighting profitability pressures. Over the period from Q1'23 to Q4'25, Gross Margin has shown overall stability with an average around 68%, though it experienced a significant dip to 30% in Q3'23 before recovering to highs of 79.3% in Q1'25. Operating and Net Profit Margins have been volatile, fluctuating between positive peaks (e.g., 34.3% and 30.3% in Q1'23, respectively) and deep negatives (e.g., -28.9% and -23.6% in Q4'23), with a pattern of intermittent losses in Q3'23, Q4'23, Q2'24, Q4'24, and Q4'25, suggesting inconsistent cost management and external factors impacting bottom-line efficiency.